Prothrombin Complex Concentrate (PCC) Market Size, Share & Trends Analysis Report By Product (3-factor PCC, 4-factor PCC), By Application (Acquired Coagulation Factor Deficiency), By End Use, By Region, And Segment Forecasts, 2023 To 2030

Prothrombin Complex Concentrate (PCC) is a medication that treats bleeding disorders resulting from deficiencies in coagulation factors II, VII, IX, and X. It is derived from human plasma and has concentrated coagulation factors. Administered intravenously, PCC quickly replenishes the coagulation factors in the bloodstream and helps restore normal clotting function. PCC is used to manage bleeding in patients with hemophilia, liver disease, other bleeding disorders, and emergencies such as trauma or surgery.

The market for Prothrombin Complex Concentrate (PCC) could grow significantly because of the use of Warfarin. Warfarin is a common treatment for blood clots that is also known to increase bleeding risk. PCC can be used to swiftly replace the coagulation factors in the blood and restore normal clotting function in cases of severe bleeding brought on by Warfarin. Patients on Warfarin are thus in high demand for PCC, and as a result, the market for PCC is anticipated to grow significantly. According to a study that appeared in the journal Thrombosis Research, more than 30 million prescriptions for Warfarin are reportedly generated each year in the U.S. alone. This demonstrates the pervasiveness of warfarin use as a medication and emphasizes the significance of maintaining its safe and efficient use by adopting a national action plan for drug event presentation.

Personalized medicine is expanding in the prothrombin complex concentrates industry, with businesses creating specialized treatments to address the requirements of different patients. This covers specialized goods for people with bleeding diseases and precise medicines for addressing certain genetic flaws. New delivery techniques, such as intranasal and subcutaneous systems, are also being developed to make treatment more practical and aid patients in following their treatment plan. For instance, in August 2022, CSL, a major global biotechnology company, marked the acquisition of Vifor Pharma and its range of products, including treatments for nephrology and rare diseases and kidney dialysis therapies, and iron deficiency. In January 2019, Grifols S.A. acquired the U.S. division of Biotest Pharmaceuticals Corporation to strengthen its presence in North America. This acquisition was expected to provide Grifols access to biotests plasma collection centers, thereby increasing the supply of plasma proteins for therapeutic use.

The market for prothrombin complex concentrates is growing globally, with North America holding a significant share owing to major manufacturers and the approval of a 4-factor PCC drug. In Europe, there is a growing use of 4-factor PCC products and favorable policies for reimbursement of medical expenses.

Prothrombin Complex Concentrate (PCC) Market Segmentation

• By Product

  • 3-factor PCC

  • 4-factor PCC

• By Application

  • Acquired Coagulation Factor Deficiency

  • Congenital Coagulation Factor Deficiency

  • Others

• By End-use

  • Hospital & Ambulatory Surgical Centers

  • Specialty Clinics

  • Others

• By Region

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Rest of Europe

  • APAC   

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of APAC

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of LATAM

  • MEA (Middle East and Africa)  

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA

• Key players

  • CSL

  • Octapharma AG

  • Kedrion

  • Takeda Pharmaceutical Company Limited.

  • Taibang Biological Group Co., Ltd.

  • Sanquin

  • Grifols, S.A.

  • Biotest AG

  • Abeona Therapeutics Inc.

  • Insud Pharma